<div id="readability-page-1"><p><span>Alignment Healthcare (NASDAQ:ALHC - Get Free Report)</span> had its price target upped by equities researchers at JPMorgan Chase &amp; Co.  from $20.00 to $23.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price indicates a potential upside of 12.03% from the company's current price.</p><p>ALHC has been the topic of several other research reports. The Goldman Sachs Group  reiterated a &#34;buy&#34; rating and issued a $22.00 target price on shares of Alignment Healthcare in a research note on Monday, November 3rd. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Alignment Healthcare in a report on Wednesday, October 8th. KeyCorp  reiterated an &#34;overweight&#34; rating on shares of Alignment Healthcare in a research note on Monday, November 24th. Barclays increased their target price on shares of Alignment Healthcare from $13.00 to $18.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, October 31st. Finally, Wall Street Zen raised shares of Alignment Healthcare from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 8th. One equities research analyst  has rated the stock with a Strong Buy rating, eight have assigned  a Buy rating, three have assigned  a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $20.35.</p><div><p><span></span><span>Get <strong>Alignment Healthcare</strong> alerts:</span></p></div><p><b>Read Our Latest Analysis on ALHC</b></p><h2>Alignment Healthcare Stock Up 2.5%</h2><p>ALHC stock traded up $0.50 during trading on Wednesday, hitting $20.53. 1,002,049 shares of the company's stock traded hands, compared to its average volume of 3,029,211. The firm has a market capitalization of $4.11 billion, a P/E ratio of -171.06 and a beta of 1.16. Alignment Healthcare has a 1 year low of $10.18 and a 1 year high of $21.06. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The business has a fifty day simple moving average of $17.77 and a two-hundred day simple moving average of $15.91. </p><p>Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.03. Alignment Healthcare had a negative return on equity of 16.23% and a negative net margin of 0.57%.The company had revenue of $993.70 million during the quarter, compared to analyst estimates of $980.90 million. During the same quarter in the prior year, the business earned ($0.14) earnings per share. Alignment Healthcare's revenue was up 43.5% on a year-over-year basis.  Sell-side analysts anticipate that  Alignment Healthcare will post -0.69 EPS for the current year. </p><h2>Insider Activity at Alignment Healthcare</h2><p>In related news, CEO John E. Kao sold 180,000 shares of the business's stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $19.02, for a total value of $3,423,600.00. Following the completion of the transaction, the chief executive officer directly owned 2,346,726 shares in the company, valued at $44,634,728.52. The trade was a 7.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Sebastian Burzacchi sold 12,585 shares of the company's stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $19.26, for a total transaction of $242,387.10. Following the completion of the transaction, the chief operating officer owned 237,793 shares of the company's stock, valued at approximately $4,579,893.18. This trade represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 842,157 shares of company stock worth $15,187,475 in the last three months. Company insiders own  6.60% of the company's stock. </p><h2>Institutional Trading of Alignment Healthcare</h2><p>A number of institutional investors and hedge funds have recently modified their holdings of ALHC. Wellington Management Group LLP increased its stake in  Alignment Healthcare by 167.3% during the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company's stock worth $193,516,000 after buying an additional 6,940,277 shares in the last quarter.  Invesco Ltd. boosted its stake in shares of  Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company's stock worth $58,387,000 after acquiring an additional 2,294,739 shares during the last quarter.  Vanguard Group Inc. boosted its stake in shares of  Alignment Healthcare by 13.2% in the first quarter. Vanguard Group Inc. now owns 11,113,896 shares of the company's stock worth $206,941,000 after acquiring an additional 1,295,825 shares during the last quarter.  Marshall Wace LLP increased its position in shares of  Alignment Healthcare by 173.3% during the second quarter. Marshall Wace LLP now owns 2,039,714 shares of the company's stock worth $28,556,000 after purchasing an additional 1,293,416 shares in the last quarter.  Finally, Voya Investment Management LLC raised its stake in  Alignment Healthcare by 61.0% in the 3rd quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company's stock valued at $55,775,000 after purchasing an additional 1,210,930 shares during the last quarter. Hedge funds and other institutional investors own  86.19% of the company's stock. </p><h2>Alignment Healthcare Company Profile</h2> (Get Free Report)<p>Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.</p><h2>Read More</h2><ul><li>Five stocks we like better than Alignment Healthcare</li><li>What is Forex and How Does it Work? </li><li>Is Tesla Overvalued? 2 Reasons It Might Be a Bargain</li><li>How to Plot Fibonacci Price Inflection Levels </li><li>How These 2 Stocks Won 2025's AI Race—And What's In Store for 2026</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>Intel Snaps Up AI Tech for Pennies on the Dollar</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxIQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxIQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alignment Healthcare Right Now?</h2><p>Before you consider Alignment Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list.</p><p>While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALHC

<p>JPMorgan Chase & Co. raised its price target for Alignment Healthcare (NASDAQ:ALHC) from $20.00 to $23.00, maintaining an "overweight" rating, indicating a potential 12.03% upside. The stock has a consensus "Moderate Buy" rating with a target price of $20.35. Recent insider trading includes significant stock sales by CEO John E. Kao and COO Sebastian Burzacchi. Institutional investors like Wellington Management and Invesco have increased their stakes in the company.</p>

JPMorgan Chase & Co. Increases Alignment Healthcare (NASDAQ:ALHC) Price Target to $23.00